{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:18:37Z","timestamp":1777393117528,"version":"3.51.4"},"reference-count":94,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>The integration of positron emission tomography\/computed tomography (PET\/CT) has revolutionized the landscape of Alzheimer\u2019s disease (AD) research and therapeutic interventions. By combining structural and functional imaging, PET\/CT provides a comprehensive understanding of disease pathology and response to treatment assessment. PET\/CT, particularly with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG), facilitates the visualization of glucose metabolism in the brain, enabling early diagnosis, staging, and monitoring of neurodegenerative disease progression. The advent of amyloid and tau PET imaging has further propelled the field forward, offering invaluable tools for tracking pathological hallmarks, assessing treatment response, and predicting clinical outcomes. While some therapeutic interventions targeting amyloid plaque load showed promising results with the reduction of cerebral amyloid accumulation over time, others failed to demonstrate a significant impact of anti-amyloid agents for reducing the amyloid plaques burden in AD brains. Tau PET imaging has conversely fueled the advent of disease-modifying therapeutic strategies in AD by supporting the assessment of neurofibrillary tangles of tau pathology deposition over time. Looking ahead, PET imaging holds immense promise for studying additional targets such as neuroinflammation, cholinergic deficit, and synaptic dysfunction. Advances in radiotracer development, dedicated brain PET\/CT scanners, and Artificial Intelligence-powered software are poised to enhance the quality, sensitivity, and diagnostic power of molecular neuroimaging. Consequently, PET\/CT remains at the forefront of AD research, offering unparalleled opportunities for unravelling the complexities of the disease and advancing therapeutic interventions, although it is not yet enough alone to allow patients\u2019 recruitment in therapeutic clinical trials.<\/jats:p>","DOI":"10.3233\/jad-240349","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:53:37Z","timestamp":1729248817000},"page":"S603-S628","source":"Crossref","is-referenced-by-count":10,"title":["Positron Emission Tomography\/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer\u2019s Disease: An\u00a0Overview of the Current State of the Art\u00a0of Research"],"prefix":"10.1177","volume":"101","author":[{"given":"Elizabeth Katherine Anna","family":"Triumbari","sequence":"first","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Chiaravalloti","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"},{"name":"IRCCS Neuromed, Pozzilli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"},{"name":"Neurology Unit, University Hospital of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"},{"name":"Neurology Unit, University Hospital of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240349_ref1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11604-019-00867-7","article-title":"Neuroimaging of Alzheimer\u2019s disease: Focus on amyloid and tau PET","volume":"37","author":"Matsuda","year":"2019","journal-title":"Jpn J Radiol"},{"key":"10.3233\/JAD-240349_ref2","first-page":"e38544","article-title":"Neuroimaging in Alzheimer\u2019s disease for early diagnosis: A comprehensive review","volume":"15","author":"Aramadaka","year":"2023","journal-title":"Cureus"},{"key":"10.3233\/JAD-240349_ref3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-240349_ref4","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","article-title":"SNMMI Procedure Standard\/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0","volume":"57","author":"Minoshima","year":"2016","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240349_ref5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate Use Criteria for Amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"54","author":"Johnson","year":"2013","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240349_ref6","doi-asserted-by":"crossref","first-page":"624330","DOI":"10.3389\/fnagi.2021.624330","article-title":"PET neuroimaging of Alzheimer\u2019s disease: Radiotracers and their utility in clinical research","volume":"13","author":"Bao","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240349_ref7","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jacr.2020.01.040","article-title":"ACR Appropriateness Criteria\u00ae Dementia","volume":"17","author":"Moonis","year":"2020","journal-title":"J Am Coll Radiol"},{"key":"10.3233\/JAD-240349_ref8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000001037","article-title":"ACR-ASNR Practice Parameter for brain PET\/CT imaging dementia","volume":"41","author":"Frey","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.3233\/JAD-240349_ref9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-021-05673-w","article-title":"International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer\u2019s disease","volume":"49","author":"Tian","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240349_ref10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/00004647-200110000-00001","article-title":"An energy budget for signaling in the grey matter of the brain","volume":"21","author":"Attwell","year":"2001","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-240349_ref11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240349_ref12","first-page":"a006213","article-title":"Brain imaging in Alzheimer disease","volume":"2","author":"Johnson","year":"2012","journal-title":"old Spring Harb Perspect Med"},{"key":"10.3233\/JAD-240349_ref13","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","article-title":"Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome","volume":"286","author":"Silverman","year":"2001","journal-title":"JAMA"},{"key":"10.3233\/JAD-240349_ref14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","article-title":"Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease: FDG-PET studies in MCI and AD","volume":"32","author":"Mosconi","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240349_ref15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","article-title":"The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease\u2014 A systematic review","volume":"94","author":"Rice","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.3233\/JAD-240349_ref16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1586\/ern.10.136","article-title":"Cerebral glucose metabolism in preclinical and prodromal Alzheimer\u2019s disease","volume":"10","author":"Herholz","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-240349_ref17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40336-013-0026-y","article-title":"Glucose metabolism in normal aging and Alzheimer\u2019s disease: Methodological and physiological considerations for PET studies","volume":"1","author":"Mosconi","year":"2013","journal-title":"Clin Transl Imaging"},{"key":"10.3233\/JAD-240349_ref18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12779\/dnd.2024.23.1.54","article-title":"The usefulness of 18F-FDG PET to differentiate subtypes of dementia: The systematic review and meta-analysis","volume":"23","author":"Na","year":"2024","journal-title":"Dement Neurocogn Disord"},{"key":"10.3233\/JAD-240349_ref19","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1073\/pnas.090106797","article-title":"Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer\u2019s disease","volume":"97","author":"Small","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240349_ref20","doi-asserted-by":"crossref","DOI":"10.4172\/978-1-63278-067-6-68","volume-title":"Alzheimer\u2019s Disease Current and Future Perspectives","author":"Dincer","year":"2016"},{"key":"10.3233\/JAD-240349_ref21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer\u2019s disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240349_ref22","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3233\/JAD-2010-100939","article-title":"A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer\u2019s disease","volume":"22","author":"Tzimopoulou","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240349_ref23","doi-asserted-by":"crossref","first-page":"e12106","DOI":"10.1002\/trc2.12106","article-title":"Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer\u2019s dementia","volume":"7","author":"Matthews","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240349_ref24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s13311-018-00708-x","article-title":"Efficacy of cilostazol administration in Alzheimer\u2019s disease patients with white matter lesions: A positron-emission tomography study","volume":"16","author":"Lee","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"Suppl 1","key":"10.3233\/JAD-240349_ref25","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.neurobiolaging.2011.09.007","article-title":"Fluorodeoxyglucose positron emission tomography: Emerging roles in the evaluation of putative Alzheimer\u2019s disease-modifying treatments","volume":"32","author":"Reiman","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240349_ref26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.3233\/JAD-240349_ref27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/01.wnl.0000269790.05105.16","article-title":"What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?","volume":"69","author":"Jagust","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JAD-240349_ref28","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.191044198","article-title":"Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose\/poitron-emission tomography (FDG\/PET)","volume":"98","author":"de Leon","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240349_ref29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s13311-010-0012-2","article-title":"Neuroimaging in dementia","volume":"8","author":"Tartaglia","year":"2011","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-240349_ref30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jalz.2011.09.172","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative: A review of papers published since its inception","volume":"8","author":"Weiner","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240349_ref31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240349_ref32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JAD-190367","article-title":"A clinical trial of transcranial electromagnetic treatment in Alzheimer\u2019s disease: Cognitive enhancement and associated changes in cerebrospinal fluid, blood, and brain imaging","volume":"71","author":"Arendash","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240349_ref33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240349_ref34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-024-01382-2","article-title":"A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer\u2019s disease","volume":"16","author":"Van Dyck","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240349_ref36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: A randomized clinical trial","volume":"76","author":"Van Dyck","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240349_ref39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer\u2019s disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240349_ref44","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11 C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J Med Chem"},{"key":"10.3233\/JAD-240349_ref45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240349_ref47","first-page":"75","article-title":"Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer\u2019s disease: Amyloid imaging positron emission tomography and safety results from a phase 2 study","volume":"3","author":"Van Dyck","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240349_ref48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trci.2015.06.007","article-title":"Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: A phase 1 clinical trial","volume":"1","author":"Kim","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240349_ref49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13195-021-00897-2","article-title":"Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: A phase I clinical trial","volume":"13","author":"Kim","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref50","doi-asserted-by":"crossref","first-page":"e101143","DOI":"10.1136\/gpsych-2023-101143","article-title":"Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer\u2019s disease: A phase I\/II clinical trial","volume":"36","author":"Xie","year":"2023","journal-title":"Gen Psych"},{"key":"10.3233\/JAD-240349_ref51","doi-asserted-by":"crossref","first-page":"fcac270","DOI":"10.1093\/braincomms\/fcac270","article-title":"Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer\u2019s disease","volume":"4","author":"Hajjar","year":"2022","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-240349_ref52","doi-asserted-by":"crossref","first-page":"102749","DOI":"10.1016\/j.nicl.2021.102749","article-title":"PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer\u2019s disease-causing Presenilin-1 E280A mutation carriers","volume":"31","author":"Ghisays","year":"2021","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JAD-240349_ref53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer\u2019s disease","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref55","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","article-title":"Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-240349_ref56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-240349_ref58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.118.209130","article-title":"Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab","volume":"60","author":"Chiao","year":"2019","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240349_ref59","first-page":"171","article-title":"Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab","volume":"10","author":"Mallinckrodt","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240349_ref60","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.3233\/JAD-240349_ref61","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer\u2019s disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JAD-240349_ref62","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240349_ref63","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: The TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240349_ref64","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240349_ref65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: A PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref67","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240349_ref68","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240349_ref69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240349_ref70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240349_ref71","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240349_ref72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/ADR-230045","article-title":"Prognostic and predictive factors in early Alzheimer\u2019s disease: A systematic review","volume":"8","author":"Garcia","year":"2024","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-240349_ref73","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s11307-022-01735-z","article-title":"Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amyloid load in Alzheimer\u2019s disease","volume":"24","author":"Sur","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.3233\/JAD-240349_ref74","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13195-021-00922-4","article-title":"Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer\u2019s disease","volume":"13","author":"Sprugnoli","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref75","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/cpt.2535","article-title":"Disease modeling and model-based meta-analyses to define a new direction for a phase III program of gantenerumab in Alzheimer\u2019s disease","volume":"111","author":"Retout","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JAD-240349_ref76","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40120-023-00473-w","article-title":"A path to improved Alzheimer\u2019s care: Simulating long-term health outcomes of lecanemab in early Alzheimer\u2019s disease from the CLARITY AD trial","volume":"12","author":"Tahami Monfared","year":"2023","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-240349_ref77","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-022-01048-x","article-title":"Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects\u2014 a MissionAD tau sub-study","volume":"14","author":"Bullich","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref78","doi-asserted-by":"crossref","first-page":"e208061","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of efficacy and safety of zagotenemab: Results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease","volume":"102","author":"Fleisher","year":"2024","journal-title":"Neurology"},{"key":"10.3233\/JAD-240349_ref79","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1002\/trc2.12415","article-title":"Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer\u2019s disease.e","volume":"9","author":"Shcherbinin","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240349_ref80","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","article-title":"The clinical use of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: A consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative","volume":"10","author":"Molinuevo","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240349_ref81","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-240349_ref82","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"key":"10.3233\/JAD-240349_ref83","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates ofPiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.3233\/JAD-240349_ref84","doi-asserted-by":"crossref","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","article-title":"Increasedamyloid-\u03b242 production, exchange, and loss in presenilin mutation carriers","volume":"5","author":"Potter","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-240349_ref85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nan.12378","article-title":"Review: Tau in biofluids \u2013 relation to pathology, imaging and clinical features","volume":"43","author":"Zetterberg","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-240349_ref86","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer\u2019s disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-240349_ref87","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-240349_ref88","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1373\/clinchem.2015.241901","article-title":"Biomarkers, assays, and therapies for Alzheimer disease","volume":"61","author":"Beriault","year":"2015","journal-title":"Clin Chem"},{"key":"10.3233\/JAD-240349_ref89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","article-title":"Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: A consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative","volume":"8","author":"Vanderstichele","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240349_ref90","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s00415-012-6413-x","article-title":"Cerebrospinal fluid and lumbar puncture: A practical review","volume":"259","author":"Wright","year":"2012","journal-title":"J Neurol"},{"key":"10.3233\/JAD-240349_ref91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2019.01.002","article-title":"Neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: A meta-analysis","volume":"50","author":"Bradburn","year":"2019","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240349_ref92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-021-00954-w","article-title":"Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer\u2019s disease dementia","volume":"14","author":"Sultzer","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240349_ref93","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.3390\/ijms25063130","article-title":"Correlation of presynaptic and postsynaptic proteins with pathology in Alzheimer\u2019s disease","volume":"25","author":"Serrano","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-240349_ref94","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.124.267767","article-title":"Performance characteristics of the NeuroEXPLORER, a next-generation human brain PET\/CT imager","volume":"65","author":"Li","year":"2024","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240349_ref95","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-022-05999-z","article-title":"PET molecular imaging for pathophysiological visualization in Alzheimer\u2019s disease","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240349_ref96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00259-023-06422-x","article-title":"Short-axis PET image quality improvement based on a uEXPLORER total-body PET system through deep learning","volume":"51","author":"Huang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240349_ref97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/978-3-031-44858-4_4","volume-title":"Machine Learning in Clinical Neuroimaging","author":"Cai","year":"2023"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:19Z","timestamp":1777370359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-240349"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":94,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240349","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}